In AML, N-cadherin+ LSC, identified as CD34+CD38–CD123+, induced disease in primary and secondary xenograft recipients, slightly more efficiently than N-cadherin– LSC (Qiu et al., 2014). Here, CD34 is linked to acute myeloid leukemia.